For Authors: Submit your work
Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression - The Lancet
The Lancet on X: "NEW—Most reliable estimates to date suggest 1 in 8 COVID-19 patients develop #longCOVID symptoms. https://t.co/wechj5flvg https://t.co/pT8lBAWS4g" / X
Robustness of evidence reported in preprints during peer review - The Lancet Global Health
Preprints and Preprint Server Update - Science Editor
eBioMedicine Home Page
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial - The Lancet
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial - The Lancet
Retracted coronavirus (COVID-19) papers – Retraction Watch
The Lancet Commission on lessons for the future from the COVID-19 pandemic - The Lancet
Preprints with The Lancet: joining online research discussion platforms - The Lancet
COVID-19 vaccine efficacy and effectiveness—the elephant (not) in the room - The Lancet Microbe
Efficacy and effectiveness of inactivated vaccines against symptomatic COVID-19, severe COVID-19, and COVID-19 clinical outcomes in the general population: a systematic review and meta-analysis - The Lancet Regional Health – Western Pacific
An interactive website tracking COVID-19 vaccine development - The Lancet Global Health
Pregnancy outcomes and vaccine effectiveness during the period of omicron as the variant of concern, INTERCOVID-2022: a multinational, observational study - The Lancet
Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis - The Lancet Microbe
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial - The Lancet Infectious Diseases
Collaborative Research: Community Health Impact Coalition Lancet Preprint - Research - Community Health Toolkit
Changes in symptomatology, reinfection, and transmissibility associated with the SARS-CoV-2 variant B.1.1.7: an ecological study - The Lancet Public Health
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial - The Lancet Infectious Diseases
Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study - The Lancet
Effectiveness of an inactivated virus-based SARS-CoV-2 vaccine, BBV152, in India: a test-negative, case-control study - The Lancet Infectious Diseases
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial - The Lancet
Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression - The Lancet Infectious Diseases
The Lancet, 14 October 2023, Volume 402, Issue 10410, Pages 1299-1392
